

## Macular Degeneration Guideline Committee – development

**Date:** Wednesday 6<sup>th</sup> September 2017

**Location:** NICE offices, Manchester

**Minutes:** Final

<b>Committee members present:</b>	
Waqar Shah (Chair)	Present for all items
Katy Barnard (KB)	Present for all items
Nick Beare (NB)	Present for all items
Cathie Burke (CB)	Present for all items
Jennifer Evans (JE)	Present for all items
Alexander Foss (AF)	Present for all items
Mary Freeman (MF)	Present for all items
Carol McCletchie (CM)	Present for all items
Ellen Rule (ER)	Present from item 3
Mary-Ann Sherratt (MS)	Present for all items
Cathy Yelf (CY)	Present for all items

<b>In attendance:</b>	
Mark Baker (MB) NICE – Centre for Guidelines Director	Present for item 3 Via telephone
Louisa Crossley (LC) NICE – Senior Medicines Advisor	Present until item 6
Jamie Elvidge (JE) NICE – Technical Analyst (HE)	Present for all items
Rupert Franklin (RF) NICE – Commissioning Manager	Present from item 5
Annette Mead (AM) NICE – Editor	Present until partway through item 6

## Macular Degeneration Guideline Committee post consultation minutes

Leslie Hayes (LH) NICE – Business Analyst	Present for all items
Yolanda Martinez (YM) NICE – Technical Analyst	Present for all items
Vonda Murray (VM) NICE – Project Manager	Present for all items
Dave Nicholls (DN) NICE – Information Specialist	Present for all items
Gabriel Rogers (GR) NICE – Technical Advisor (HE)	Present for all items
Sue Spiers (SS) NICE – Associate Director	Present for all items

### Observers:

Susannah Moon – NICE Programme Manager	Present until item 4
Judith Hughes – PhD student	Present until item 5

### Apologies:

Andy Charley	Committee member
Elizabeth Wick (EW)	Committee member

### Item 1 Introductions, apologies, minutes, DOI and objectives for the meeting

The Chair welcomed the Committee members and attendees to the post consultation meeting on age-related macular degeneration (AMD). The committee members, attendees and observers introduced themselves.

Apologies were noted, as recorded above. It was noted that RF, AM, ER,

and would join the meeting the meeting later in the day.

The Chair invited each attendee to declare any new conflicts since the previous meeting. The following conflicts were noted;

<b>Attendee</b>	<b>Declaration</b>	<b>Action</b>
Jennifer Evans (JE)	Will be presenting at the Glaucoma Society. No honorarium	Declare and participate
Mary-Ann Sherratt (MS)	Approached by Roche to be a dry AMD advisor on a committee, declined the offer	Declare and participate

Having reviewed all previous and new declarations of interest it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The minutes were reviewed from GComm 13; 13<sup>th</sup> February 2017. It was noted that Joshua Pink had been omitted from the attendance list. The minutes were agreed to be an accurate record subject to the amendment noted above.

**Update the attendance list to include Joshua Pink on the attendance list VM**

The Chair provided an overview of the objectives for the day highlighting the information that would be discussed.

**Item 2  
Stakeholder consultation comments and committee discussion**

GR lead a discussion with the committee on the stakeholder comments on anti-oxidants following consultation. The committee agreed the

responses to the stakeholder comments and any necessary changes to the guideline and / or recommendations.

**Item 3**

**Discussion with Mark Baker**

MB joined the committee to provide an overview of the process and decisions relating to the inclusion of recommendations relating to anti-VEGF treatment in the draft guideline submitted for consultation. He clarified that the initial recommendations which had been submitted by the committee had been reviewed by NICE's lawyers, and discussed with representatives from the Department of Health and the MHRA. Consequently, a number of changes were made to the recommendations to ensure that they accurately reflected the current legal position regarding bevacizumab.

MB further addressed concerns raised by individual committee members in responding to stakeholder consultation comments and explained the process which will be followed in the lead up to final approval of the guideline by NICE's Guidance Executive ahead of publication.

The committee then agreed the responses to the stakeholder comments and any necessary changes to the guideline and / or recommendations on anti-VEGF treatment

**Item 4**

**Stakeholder consultation comments and committee discussion**

GR and JE presented new health economic evidence on anti-VEGF treatment, and highlighted how this effects the economic model for macular degeneration.

**LUNCH**

**Item 5**

**Stakeholder consultation comments and committee discussion**

JE continued to present the health economic data on anti-VEGF treatment. The committee discussed the evidence.

GR led a discussion with the committee on the stakeholder comments on anti-VEGF following consultation. The committee agreed the responses to the stakeholder comments and any necessary changes to the guideline

and / or recommendations.

**Item 6**  
**Stakeholder consultation comments and committee discussion**

GR led a discussion with the committee on the stakeholder comments in the following areas:

- time to referral
- switching anti-VEGF treatment
- PDT

The committee agreed the responses to the stakeholder comments and any necessary changes to the guideline and / or recommendations.

**Item 7**  
**Publication process**

Due to time constraints, this item was rescheduled for a further post-consultation meeting.

**Item 8**  
**Summary and next steps**

The Chair briefly summarised the discussions from the meeting, and thanked the committee members for their input.

The Chair consulted with the committee about the opportunity to have a further half day meeting to continue the discussion of the consultation comments. The committee agreed that this would be useful.

**VM to arrange a half day post consultation meeting**